文献速递造血干细胞移植与细胞治疗

阻断供体移植物TIM-1减轻造血细胞移植后移植物抗宿主病

Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

该研究在小鼠模型中探讨TIM-1在急性GVHD中的作用,发现拮抗性抗TIM-1单抗可保护免受急性GVHD并维持移植物抗肿瘤效应,而外源性游离磷脂酰丝氨酸以TIM-1依赖方式加重GVHD。TIM-1阻断不改变供体T细胞扩增,而是减少促炎因子并促进抗炎因子;在人源化小鼠异种移植GVHD模型中,抗人TIM-1拮抗性单抗降低GVHD疾病负担和死亡率。

要点

  • 拮抗性抗TIM-1单抗在小鼠中预防急性GVHD且保留移植物抗肿瘤效应
  • TIM-1阻断不改变供体T细胞扩增,而是调节肠道促炎/抗炎因子平衡
  • 供体invariant NKT细胞上的TIM-1驱动炎症,是保护效应的关键

核心结论

  • TIM-1在急性GVHD发病机制中起重要作用,是预防GVHD的潜在靶点。

研究设计与样本

  • 采用小鼠模型及人源化小鼠异种移植GVHD模型,使用拮抗性抗TIM-1单抗及TIM-1敲除小鼠进行机制研究。

主要发现

  • 拮抗性抗TIM-1单抗保护小鼠免受急性GVHD,同时维持移植物抗肿瘤效应。
  • 外源性游离磷脂酰丝氨酸以TIM-1依赖方式加重GVHD。
  • TIM-1阻断不改变供体T细胞体外或体内扩增,但减少肠道促炎因子并促进碳酸酐酶1和血清淀粉样蛋白A1等抗炎因子。
  • 供体TIM-1敲除的常规T细胞或骨髓移植给野生型受体可改善生存,部分归因于供体invariant NKT细胞上的TIM-1驱动炎症。
  • 人源化小鼠模型中,抗人TIM-1拮抗性单抗降低GVHD疾病负担和死亡率。

临床怎么用

  • 靶向供体移植物TIM-1可能成为预防急性GVHD并保留移植物抗肿瘤效应的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (GVHD) is a leading cause of mortality after allogeneic hematopoietic cell transplantation (HCT) mediated by dysregulated T-cell immune reconstitution. Given the role of the T-cell immunoglobulin and mucin 1 (TIM-1) surface protein in many immune processes, including organ transplantation tolerance, we asked if TIM-1 might drive post-transplant inflammation and acute GVHD. TIM-1 binds to phosphatidylserine (PtdSer), and agonism of TIM1 on immune cells is proinflammatory. HCT conditioning results in a significant supply of PtdSer from apoptosis and cellular debris. Using murine models, treatment with an antagonistic anti-TIM-1 monoclonal antibody (mAb) protects against acute GVHD while maintaining graft-versus-tumor effects. In contrast, the addition of exogenous free PtdSer worsened GVHD in a TIM-1-dependent manner. Importantly, TIM-1 blockade did not alter the expansion of donor T cells in vitro or in vivo. Instead, TIM-1 blockade reduces proinflammatory cytokines and promotes anti-inflammatory factors like carbonic anhydrase 1 and serum amyloid A1 in the gut tissue. This is mediated by TIM-1 on donor cells, as HCT of wild-type (WT) bone marrow (BM) and conventional T (Tcon) cells into TIM-1-/- knockout (KO) recipient mice showed little survival advantage compared with WT recipients, whereas WT recipients of TIM-1-/- KO Tcon cells or TIM1-/- KO BM had improved survival, in part due to the expression of TIM-1 on donor invariant natural killer T cells, which drives inflammation. Finally, in a humanized mouse xenograft GVHD model, treatment with anti-human TIM-1 antagonist mAb reduced GVHD disease burden and mortality. This supports TIM-1 as important for GVHD pathogenesis and as a target for the prevention of GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Iliopoulou BP, Hsu K, Pérez-Cruz M, et al. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Adv. 2019. PMID: 31714958. doi:10.1182/bloodadvances.2019000286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。